- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06838273
Исследование BL-B01D1 в сочетании с осимертинибом по сравнению с Osimertinib в качестве лечения первой линии у пациентов с EGFR-мутированным локально распространенным или метастатическим немелкоклеточным раком легких
Рандомизированное исследование фазы III BL-B01D1 в сочетании с осимертинибом по сравнению с Osimertinib в качестве лечения первой линии у пациентов с EGFR-мутированным локально распространенным или метастатическим немелкоклеточным раком легких
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib as first-Line treatment in patients with EGFR-mutated locally advanced or metastatic Non-small Cell Lung Cancer.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Китай
- Shanghai East Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Sign the informed consent form voluntarily and follow the protocol requirements;
- Age ≥18 years old;
- Expected survival time ≥3 months;
- Patients with unresectable or radical radiotherapy for locally advanced non-small cell lung cancer;
- Documentation of EGFR sensitive mutations detected from tumor tissue or blood samples;
- Consent to provide archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions at or after diagnosis for testing, including EGFR mutation type;
- At least one measurable lesion meeting the RECIST v1.1 definition was required;
- ECOG 0 or 1;
- The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
- No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
- The organ function level must meet the requirements on the premise that blood transfusion and colony-stimulating factor are not allowed within 14 days before the screening period;
- Urinary protein ≤2+ or < 1000mg/24h;
- For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.
Exclusion Criteria:
- Previous histologic or cytological evidence of small cell or mixed small/non-small cell components;
- Patients with previous systemic therapy;
- Patients had received EGFR-TKI therapy;
- Studies received radical radiotherapy, major surgery, and large area radiotherapy within 4 weeks before randomization;
- History of severe heart disease and cerebrovascular disease;
- Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;
- QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
- Were diagnosed with active malignancy within 3 years before randomization;
- Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg);
- Patients with poor glycemic control;
- A history of ILD requiring steroid therapy, or current ILD or grade ≥2 radiation pneumonitis, or a suspicion of such disease;
- Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;
- Patients with active central nervous system metastasis;
- Had a severe infection within 4 weeks before randomization;
- Patients with massive or symptomatic effusions or poorly controlled effusions;
- Imaging examination showed that the tumor had invaded or enveloped the large blood vessels in the abdomen, chest, neck, and pharynx;
- Serious unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;
- Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
- Patients with a history of inflammatory bowel disease, extensive bowel resection, immune enteritis, intestinal obstruction or chronic diarrhea;
- Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of BL-B01D1;
- Had autologous or allogeneic stem cell transplantation history;
- Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;
- A history of severe neurological or psychiatric illness;
- Received other unmarketed investigational drugs or treatments within 4 weeks before randomization;
- Subjects scheduled for vaccination or who received live vaccine within 28 days before study randomization;
- Other circumstances in which the investigator considered it inappropriate to participate in the trial because of complications or other circumstances.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: BL-B01D1 in Combination with Osimertinib
Participants receive BL-B01D1 in Combination with Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons. |
Administration by intravenous infusion for a cycle of 3 weeks.
Другие имена:
Oral administration, 80mg daily for a cycle of 3 weeks. |
|
Активный компаратор: Osimertinib
Participants receive Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons. |
Oral administration, 80mg daily for a cycle of 3 weeks. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression-free survival (PFS)
Временное ограничение: Up to approximately 36 months
|
Progression-free survival (PFS) as assessed by BIRC is defined as the time between the date subjects are randomized and the first observation of disease progression (based on BICR's image-based assessment) or death. |
Up to approximately 36 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Overall survival (OS)
Временное ограничение: Up to approximately 36 months
|
Overall survival (OS) is defined as the time between the subject's randomization date and subject's death. |
Up to approximately 36 months
|
|
Objective Response Rate (ORR)
Временное ограничение: Up to approximately 36 months
|
Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS). |
Up to approximately 36 months
|
|
Disease Control Rate (DCR)
Временное ограничение: Up to approximately 36 months
|
Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria. |
Up to approximately 36 months
|
|
Duration of Response (DOR)
Временное ограничение: Up to approximately 36 months
|
Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death. |
Up to approximately 36 months
|
|
Treatment Emergent Adverse Event (TEAE)
Временное ограничение: Up to approximately 36 months
|
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1. |
Up to approximately 36 months
|
|
Anti-drug antibody (ADA)
Временное ограничение: Up to approximately 36 months
|
Frequency of anti-BL-B01D1 antibody (ADA) will be investigated. |
Up to approximately 36 months
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- BL-B01D1-308
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .